Immune regulation therapy: inflammatory bowel disease - Enzo Biochem

Drug Profile

Immune regulation therapy: inflammatory bowel disease - Enzo Biochem

Alternative Names: Alequel; Immune modulation technology - Enzo Biochem

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzo Biochem
  • Class Antigens
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease

Most Recent Events

  • 04 Aug 2015 Phase-II development is ongoing in Israel
  • 30 May 2007 Data presented at Digestive Disease Week-2007 (DDW-2007) added to the adverse events and Inflammatory Bowel Disorders therapeutic trials sections
  • 30 Sep 2004 Data from a phase II trial have been added to the Inflammatory Bowel Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top